Clinical Trial Update: A Study Of TL-925 For The Treatment of AC [Phase 2]

View source ↗

Summary

TL-925 was evaluated in a Phase 2 trial for allergic conjunctivitis, and the study has completed; the document does not disclose results in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• TL-925

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED